*僅供醫學專業人士閱讀參考

埃萬妥單抗聯合蘭澤替尼實現總生存期（OS）與無進展生存期（PFS）獲益顯著提升。

*以下內容僅供醫療衛生專業人士瀏覽。

參考文獻：

[1]中國臨床腫瘤學會非小細胞肺癌專家委員會，國家癌癥中心肺癌質控專家委員會. EGFR-TKIs耐藥后應對策略及標準化質量控制中國專家共識[J]. 中國腫瘤臨床與康復，2025，32(9)：547-572.

[2]Yang JC, et al. Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2025;393(17):1681-1693.

[3]Cho BC, et al. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N Engl J Med. 2024;391(16):1486-1498.

[4]Cho BC, et al. Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset. Lung Cancer. 2025;204:108496.

[5]Moores SL, et al. A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors. Cancer Res. 2016;76(13):3942-3953.

[6]Vijayaraghavan S, et al. Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis. Mol Cancer Ther. 2020;19(10):2044-2056.

[7]Lee J, et al. Lazertinib: on the Way to Its Throne. Yonsei Med J. 2022;63(9):799-805.

[8]Hayashi H, et al. Mechanisms of acquired resistance to first-line amivantamab plus lazertinib vs osimertinib:updated analysis from MARIPOSA. 2025 WCLC PT1.03.06.

[9]Besse B, et al. Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study. Ann Oncol 2024;35:Suppl 2: S1245-S1246.

[10]Sperduto PW, et al. Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. J Clin Oncol. 2020;38(32):3773-3784.

[11]NCCN Guidelines Version 2.2025 Brain Metastases

審批編碼：CP-552510
批準分發日期：11/14/2025
有效期：11/14/2026

*此文僅用于向醫療衛生專業人士提供科學信息，不代表平臺立場。